Viberzi denied as experimental or investigational by Cigna?

Cigna's specific coverage criteria for viberzi are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna May Deny Viberzi as Experimental

An experimental or investigational denial means Cigna concluded that Viberzi (eluxadoline) lacks sufficient evidence of safety and effectiveness under its coverage policy. This denial category is sometimes triggered by outdated policy language or a misapplication of the policy to an FDA-approved drug. Viberzi is an FDA-approved prescription treatment for irritable bowel syndrome with diarrhea (IBS-D) in adults, which is the cornerstone of any appeal against an experimental denial.

## Why This Denial Is Appealable

FDA approval is a legally significant milestone: the agency has reviewed the drug's safety and efficacy data and determined it meets the standard for marketing authorization. An insurer's "experimental" classification that contradicts FDA approval is a strong candidate for reversal on appeal. In addition, gastroenterology professional societies have recognized eluxadoline in their IBS-D management guidance, further supporting medical acceptance.

## Your Federal Appeal Rights

Under ACA §2719, you have the right to an internal appeal and then an independent external review by an accredited Independent Review Organization (IRO). Under ERISA §503, self-funded employer plans must conduct a full-and-fair review. The external-review window is generally approximately four months from the denial date. Expedited external review is available when standard timelines would jeopardize your health or ongoing treatment.

## The Appeal Process

1. Obtain the denial letter and the coverage policy. The policy should specify what criteria Cigna uses to classify a drug as experimental. Request the exact version applied to your claim. 2. Level 1 internal appeal. Respond in writing within the deadline on your denial notice. Attach the FDA approval documentation and your prescriber's medical-necessity letter. 3. External review. If the internal appeal fails, escalate to an IRO. IROs are required to evaluate clinical evidence independently of Cigna's internal guidelines.

## Documentation to Gather

• FDA approval status: A printout or citation of the FDA-approved prescribing label for eluxadoline confirming the approved indication.
• Diagnosis confirmation: Physician notes and any relevant diagnostic workup confirming IBS-D.
• Prescriber letter: A detailed letter citing FDA approval, the relevant gastroenterology society guideline organization's position on IBS-D management, and the clinical rationale for this specific patient.
• Prior treatment history: Documentation of earlier IBS-D therapies tried, with dates and outcomes, demonstrating the need for this treatment.

## Criteria-Mapping Structure

Obtain Cigna's medical coverage policy for eluxadoline. List each criterion the policy uses to define "not experimental" or "medically accepted," then match each criterion to a specific piece of evidence: FDA label language, guideline organization statements, and chart-based clinical facts. A direct, criterion-by-criterion rebuttal is far more persuasive than a general objection.